1523 related articles for article (PubMed ID: 33253941)
1. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
[TBL] [Abstract][Full Text] [Related]
2. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
3. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.
Gégout Petit A; Jeulin H; Legrand K; Jay N; Bochnakian A; Vallois P; Schvoerer E; Guillemin F
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200070
[TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
[TBL] [Abstract][Full Text] [Related]
6. The importance of anosmia, ageusia and age in community presentation of symptomatic and asymptomatic SARS-CoV-2 infection in Louisiana, USA; a cross-sectional prevalence study.
Feehan AK; Fort D; Velasco C; Burton JH; Garcia-Diaz J; Price-Haywood EG; Sapp E; Pevey D; Seoane L
Clin Microbiol Infect; 2021 Apr; 27(4):633.e9-633.e16. PubMed ID: 33421576
[TBL] [Abstract][Full Text] [Related]
7. The seroprevalence of SARS-CoV-2 in a rural southwest community.
Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
[TBL] [Abstract][Full Text] [Related]
8. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.
Kataria Y; Cole M; Duffy E; de la Cena K; Schechter-Perkins EM; Bouton TC; Werler MM; Pierre C; Ragan EJ; Weber SE; Jacobson KR; Andry C
Sci Rep; 2021 May; 11(1):9694. PubMed ID: 33958668
[TBL] [Abstract][Full Text] [Related]
11. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
[TBL] [Abstract][Full Text] [Related]
13. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003.
Tseng WP; Wu JL; Wu CC; Kuo KT; Lin CH; Chung MY; Lee YF; Yang BJ; Huang CH; Chen SY; Yu CJ; Chen SC; Hsueh PR
Front Immunol; 2021; 12():626609. PubMed ID: 34084161
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of COVID-19 Virus Infection in Semnan province.
Jandaghi E; Hemati M; Mohammadlou M; Jandaghi J; Mirmohammadkhani M; Danaei N; Kokhaei P
Iran J Immunol; 2021 Mar; 18(1):74-81. PubMed ID: 33787516
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland.
Kasztelewicz B; Janiszewska K; Burzyńska J; Szydłowska E; Migdał M; Dzierżanowska-Fangrat K
PLoS One; 2021; 16(4):e0249550. PubMed ID: 33793673
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study.
Mahajan S; Srinivasan R; Redlich CA; Huston SK; Anastasio KM; Cashman L; Massey DS; Dugan A; Witters D; Marlar J; Li SX; Lin Z; Hodge D; Chattopadhyay M; Adams MD; Lee C; Rao LV; Stewart C; Kuppusamy K; Ko AI; Krumholz HM
Am J Med; 2021 Apr; 134(4):526-534.e11. PubMed ID: 33130124
[TBL] [Abstract][Full Text] [Related]
19. High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo.
Batchi-Bouyou AL; Lobaloba Ingoba L; Ndounga M; Vouvoungui JC; Mfoutou Mapanguy CC; Boumpoutou KR; Ntoumi F
Int J Infect Dis; 2021 May; 106():3-7. PubMed ID: 33370565
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.
Letizia AG; Ge Y; Vangeti S; Goforth C; Weir DL; Kuzmina NA; Balinsky CA; Chen HW; Ewing D; Soares-Schanoski A; George MC; Graham WD; Jones F; Bharaj P; Lizewski RA; Lizewski SE; Marayag J; Marjanovic N; Miller CM; Mofsowitz S; Nair VD; Nunez E; Parent DM; Porter CK; Santa Ana E; Schilling M; Stadlbauer D; Sugiharto VA; Termini M; Sun P; Tracy RP; Krammer F; Bukreyev A; Ramos I; Sealfon SC
Lancet Respir Med; 2021 Jul; 9(7):712-720. PubMed ID: 33865504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
